In downstream mechanisms, ITGB7 significantly promoted CHD progression by regulating immune cells, such as CD4+ CD8dim AC (beta_p = 12.04%), and plasma metabolites, including N,N‐dimethylalanine (beta_p = 18.96%), benzoate‐to‐oleoyl–linoleoyl–glycerol (18:1 to 18:2) ratio (beta_p = 34.63%), and serine‐to‐threonine ratio (beta_p = 12.58%). The gene discussed is ITGB7; the disease is coronary artery disorder.